More than ten cattle were diagnosed with bovine brucellosis in each of the last several years using serological testing during import quarantine. However, Brucella abortus has not been isolated from the samples of the cattle. In 2008, a bacterium biochemically closed to the genus Brucella was isolated from the lung of one of the feeder cattle imported from Australia, which was serologically diagnosed with brucellosis during import quarantine. The bacterium tested positive in a plate agglutination test for Brucella-specific antisera, and tested positive in a PCR assay for Brucella spp. The bacterium was identified as Ochrobactrum intermedium by PCR assay of the recA genes and genetic analysis using 16s rRNA. The PCR assay of recA genes and the growth on SSagar is useful for identifying Ochrobactrum spp. and Brucella spp.
Twenty-eight strains of enterotoxigenic Escherichia coli (ETEC) and shigatoxin-producing E. coli (STEC) isolated from 27 diarrheic calves between 1996 and 2009 in Okinawa Prefecture, were investigated for antimicrobial susceptibility and antimicrobial resistance genes. The ETEC isolates (n ＝14) showed five antimicrobial resistance patterns : ABPC-SM-KM-OTC-CP-NA (one strain), ABPC-SM-OTC-CP-NA-ST (one), ABPC-SM-OTC-CP-ST (six), SM-KM-OTC-NA (one) and SM-OTC-CP-ST (five). STEC isolates (n＝14) showed four drug-resistance patterns : ABPC-SM-KM-OTC (two), ABPC-SM-OTC-ST (one), SM-GM-ST (one) and SM-OTC (six). These results suggested that ETEC and STEC isolates were identified for six and eight resistance genotypes, respectively, and ETEC/STEC isolates with the same resistance phenotypes often have different resistance genotypes.
Plasma potassium concentrations were measured in 54 dogs with mitral regurgitation that were administered chronically with an angiotensin-converting enzyme inhibitor (ACEI), with or without spironolactone. During the administration period of 3 to 95 months, clinical sings tended to progress gradually, with radiographic cardiac sizes tending to be large after 45 months. During the administration period, obvious and persistent hyperkalemia was not detected in dogs administered with ACEI, with or without spironolactone. The present data indicate that the combined use of the AECI and spironolactone can be considered in dogs with mitral regurgitation, although monitoring of plasma electrolytes is necessary.
An infectious endogenous retrovirus termed the RD114 virus is present in the genome of domestic cats, and as such has the potential to contaminate feline live attenuated vaccines manufactured using feline cells for cultivation. Recently, Miyazawa et al. reported that infectious RD114 viruses were present in certain live attenuated vaccines [Journal of Virology]. In this study, we attempted to confirm the presence of the virus in feline live multivalent vaccines (four products, 30 batches) approved in Japan by the LacZ marker rescue assay. Thirty percent of the vaccines tested were found to be positive for the infectious RD114 virus. This report confirms the presence of infectious RD114 virus in feline vaccines under the present experimental design. The pathogenicity of the RD114 virus and the adverse effects on cats of inoculation with feline live attenuated vaccines are unknown at present. Nevertheless, the same vaccines have been sold in European countries and in the United States. As the regulatory authority of Japan, we have decided not to take urgent action, such as banning the sale of vaccines containing the RD114 virus, and will continue to collect information about the virus and monitor any issues that may arise.
A 12-year-old male mixed dog and a 10-year-old male Great Pyrenees presented with a unilateral mandibular mass. Computed tomography revealed distant metastases to the lung and/or liver. Cytological or histological examination revealed malignant neoplasms consisting of epithelial cells. In one case, tumoral cells were positive for COX-2 immnohistochemistry. These cases were treated with radiotherapy and a selective COX-2 inhibitor, and achieved long-term remission. These results support the recommendation of radiotherapy and a selective COX-2 inhibitor for salivary gland tumors.